Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed...
Month: August 2023
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical...
Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium
ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an...
Bionano Announces Second OEM Partner has Received China NMPA Approval for DNA Extraction and Labeling Products for IVD Use of OGM in Reproductive Health
Bionano original equipment manufacturing (OEM) partner A-smart MedTech (A-smart) obtained reagent class I registration and approval for DNA isolation and...
Atsena Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisis
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling male patients ages 6-64 with...
Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics
Financing led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels Superluminal combines deep biology and chemistry...
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical...
LEXEO Therapeutics Announces Strategic Investment from Sarepta Therapeutics to Support Development of LEXEO’s Cardiovascular Gene Therapies
Companies to explore collaboration opportunities within LEXEO’s preclinical cardiovascular pipelineNEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO),...
Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED)
Phase 2b trial of TOUR006 is expected to report top-line clinical data in the first half of 2025NEW YORK, Aug....
Aurora Spine Corporation Schedules Conference Call to Update Investors and Discuss Second Quarter Fiscal Year 2023 Financial Results
CARLSBAD, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),...
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations...
ONL Therapeutics Completes Enrollment in Phase 2 Study of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204...
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein...
Genelux Corporation Announces New Chief Financial Officer
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced...
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and...
Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders®
Sub-group analyses of patients with early Parkinson's disease (PD) at different age groups or baseline disease severities who were treated...
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for...
CLS Americas and Focalyx Co-Marketing Agreement for Image-Guided Focal Laser Ablation of Prostate Tumors Using TRANBERG and Focalyx Fusion Systems
Minimally Invasive, Outpatient Treatment Designed for Quick Recovery and Low Risk of Unwanted ED and UI Side EffectsIRVINE, Calif. and...
Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%
BAUDETTE, Minn., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that...